SUBMISSION NOTE: This represents a 3rd Party email communication. 
HEADER AREA: This area is reserved for the: From, To, and customized headers for any 3rd Party vendor that will deploy this email. 
Note: Not all 3rd Party vendors may use a header. 
3rd PARTY FOOTER AREA: This area is reserved for a 3rd Party vendor footer which includes the vendor's opt-out language and 
link. 
3rd PARTY FOOTER AREA: This area is reserved for a 3rd Party vendor footer which includes the vendor's opt-out language and link.ImportantupdateforaGenentechproduct
Important Update inHR-Positive, HER2-Negative,
Locally Advanced orMetastatic Breast
Treatmentrecommendation
NCCNClinicalPracticeGuidelinesinOncology
(NCCNGuidelines®) forBreastCancerrecommend
inavolisib
Category
HR+/HER2-
adiuvantendocrine orrelapse
monthsofcompletingadjuvantendocrine
diseasewithnovisceralcrisisinpatientswhoarepostmenopausal orpremenopausaltreatedwithovarian
Wal
(inavolisib),incombination withpalbociclibandfulvestrant,isindicatedfor
thetreatmentofadultswithendocrine-resistant, hormone(HR)-
positive,humanepidermalgrowth-factor receptor2(HER2)-negative, locally
advancedormetastaticbreastcancer,asdetectedbyanFDA-approved test,
followingrecurrenceonoraftercompletingadjuvantendocrinetherapy.
ImportantSafetyInformation
WarningsandPrecautions
ltovebihaswarningsandprecautionsforhyperglycemia, stomatitis,diarrhea,and
embryo-fetal toxicity.
PleaseseeadditionalImportantSafetyInformation below.
TheFIRSTandONLYregimenwith ImportantSafety
mPFSvspalbociclib andfulvestrant, basedInformation
ontheINAVO120
Warningsand
Precautions
haswarningsand
precautionsfor
hyperglycemia,
stomatitis,diarrhea,and
embryo-fetal toxicity.
Hyperglycemia
Severehyperglycemia
canoccurinpatients
treatedwith
Increasedfasting
glucoseoccurredin85%
ofpatientstreatedwith
including22%of
natientswithGrade
(FPG>160to250
mg/dL),12%withGrade
3(FPG>250to500
mg/dL),and0.6%with
Grade4(FPG>500
mg/dL)events.
InINAVO120,46%
(74/162)ofpatientswho
received were
treatedwithoralanti-
hyperglycemic
medicationsand7%
(11/162)weretreated
withinsulintomanage
increasedfasting
glucose.Inpatientswho
increased
fastingglucoseof>160
mg/dL,96%(52/54)had
animprovement in
fastingglucoseofat
leastonegradelevel
withatimeto
improvement fromthe
firsteventof8days
(range:2to43days).
Amongpatientswith
hyperglycemia, the
mediantimetofirstonset
wasdays(range:2to
955days).
Hyperglycemia ledto
doseinterruntionin28%.
todosereductionin
2.5%,andto
discontinuation of
in1.2%ofpatients.
Thesafetyofin
patientswithType1
diabetesmellitus.or
Type2diabetesmellitus
requiringongoinganti-
hyperglycemic treatment
havenotbeenstudied.
Beforeinitiating
treatmentwith
testfastingglucose
levels(FPGorFBG),
levels,and
optimizefastingglucose.
ImportantSafety
Information
continued below.
AfterinitiatingtreatmentwithItovebiorinpatientswhoexperiencehyperglycemia
afterinitiatingtreatmentwithmonitororself-monitorfastingglucoselevels
onceevery3daysforthefirstweek(Day1to7),thenonceeveryweekforthenext
3weeks(Day8to28),thenonceevery2weeksforthenext8weeks,thenonce
every4weeksthereafter,andasclinicallyindicated.Monitor every3months
andasclinicallyindicated.
Managehyperglycemia withanti-hyperglycemic medicationsasclinicallyindicated.
Duringtreatmentwithanti-hyperglycemic medication,continuemonitoringfasting
glucoselevels.Patientswithahistoryofwell-controlled Type2diabetesmellitusmay
requireintensifiedanti-hyperglycemic treatmentandclosemonitoringoffasting
glucoselevels.
Considerconsultationwithahealthcareprofessional experienced inthetreatmentof
hyperglycemia, andinitiationoffastingglucosemonitoringathomeforpatientswho
haveriskfactorsforhyperglycemia orwhoexperiencehyperglycemia. Advise
patientsofthesignsandsymptomsofhyperglycemia andcounselpatientson
lifestylechanges.
Basedontheseverityofthehyperglycemia, mayrequiredoseinterruption,
reduction,ordiscontinuation.
Stomatitis
Severestomatitiscanoccurinpatientstreatedwith
Stomatitisoccurredin51%ofpatientstreatedwithItovebiincombination with
palbociclibandfulvestrant,includingGrade3eventsin6%ofpatients.Themedian
timetofirstonsetwas13days(range:1to610days).Stomatitisledtointerruption
ofItovebiin10%,todosereductionin3.7%,andtodiscontinuation ofin0.6%
ofpatients.
InpatientswhoreceivedItovebiincombination withpalbociclibandfulvestrant,38%
usedamouthwashcontainingcorticosteroid formanagement orprophylaxisof
stomatitis.
Monitorpatientsforsignsandsymptomsofstomatitis.Withhold,reducedose,or
permanently discontinue basedonseverity.
Diarrhea
Severediarrhea,includingdehydrationandacutekidneyinjury,canoccurinpatients
treatedwith
Diarrheaoccurredin48%ofpatientstreatedwithincombinationwith
palbociclibandfulvestrant;includingGrade3eventsin3.7%ofpatients.Themedian
timetofirstonsetwas15days(range:2to602days).Anti-diarrheal medicineswere
usedin28%(46/162)ofpatientswhoreceivedItovebiincombination with
palbociclibandfulvestranttomanagesymptoms.Doseinterruptions wererequiredin
7%ofpatients,anddosereductionsoccurredin1.2%.
Monitorpatientsforsignsandsymptomsofdiarrhea.Advisepatientstoincreaseoral
fluidsandstartanti-diarrheal treatmentatthefirstsignofdiarrheawhiletaking
Withhold,reducedose,orpermanently discontinue basedon
severity.
Embryo-Fetal Toxicity
Basedonfindingsinanimalsanditsmechanismofaction, cancausefetal
harmwhenadministered toapregnantwoman.Inananimalreproduction study,oral
administration ofinavolisibtopregnantratsduringtheperiodoforganogenesis
causedadversedevelopmental outcomes,includingembryo-fetal mortality,structural
abnormalities, andalterationstogrowthatmaternalexposuresapproximately
equivalenttothehumanexposureattherecommended doseof9mg/daybasedon
areaunderthecurve(AUC).
Advisepregnantwomenandfemalesofreproductive potentialofthepotentialriskto
afetus.Advisefemalesofreproductive potentialtouseeffectivenon-hormonal
contraception duringtreatmentwithandfor1weekafterthelastdose.Advise
malepatientswithfemalepartnersofreproductive potentialtouseeffective
contraception duringtreatmentwithItovebiandfor1weekafterthelastdose.
MostCommonAdverseReactions
Themostcommon(220%)adversereactions,includinglaboratoryabnormalities,
weredecreasedneutrophils,decreasedhemoglobin, increasedfastingglucose,
decreasedplatelets,decreasedlymphocytes, stomatitis, decreased
calcium,fatigue,decreasedpotassium,increasedcreatinine,increasedALT,nausea,
decreasedsodium,decreasedmagnesium, rash,decreasedappetite,COVID-19
infection,andheadache.
YoumayreportsideeffectstotheFDAat1-800-FDA-1088 or
www.fda.gov/medwatch. YoumayalsoreportsideeffectstoGenentechat
leaseseethefullPrescribing Information foradditionalImportantSafety
Information.
line;ALT=alanineaminotransferase; DOR=durationofresponse;FDA=USFoodandDrug
stration;HR=hazardratio; breastcancer;mPFS=medianprogression-free
responserate;OS=overall
osito
Prescribinginformation.Genentech,Inc.;2025.
ReferencedwithpermissionfromtheNCCNClinicalPracticeGuidelinesinOncology(NCCN
Guidelines®)forBreastCancerV.1.2025.©NationalComprehensive CancerNetwork,Inc.2025
Allrightsreserved.AccessedFebruary19,2025.Toviewthemostrecentandcompleteversion
oftheguideline,goonlinetowww.NCCN.org.
3.JnaveriKL,ImS-A,SauraC,etal.Inavolisiborplaceboincombinationwithpalbocicliband
fulvestrantinpatientswithPIK3CA-mutated, hormonereceptor-positive, HER2-negative locally
advancedormetastaticbreastcancer:phaseIIIINAVO120primary
AntonioBreastCancerSymposium;December5-9,2023;SanAntonio,
Genentech
AMembe
ContactUsPrivacyPolicyTermsandConditionsUnsubscribe
ThiscommercialemailisbroughttoyoubyGenentech.
emailisintendedforUShealthcareprofessionalsonly
anditslogoaretrademarksofGenentech,In
©2025GenentechUSA,Inc.Allrightsreserved.
GenentechUSA,Inc.1DNAWaySouthSanFrancisco,CA94080-4990Viewinbrowse!
PrescribingInformation
ImportantSafetyInformation
NCCN
CATEGORY 1
TREATMENT OPTION
anv
Indicationy1treatme
rantiesofanykindwhatsoeverregardingtheircontent,use,orapplication,anddisclaims
heirapplicationoruseinanyway.SeetheNCCNGuidelines®fordetailed+palbociclibandfulvestrantas
optionfor
diseaseprogressionon
within
TL
ted.2NOONGuidelines useInanvwav.
Studydesign:INAVO120wasaphase3,
randomized, double-blind, placebo-controlled study,
evaluatingtheefficacyandsafetyofin
combination withpalbociclibandfulvestrantinadult
patientswithPIK3CA-mutated, HR+/HER2- mBC
whosediseaseprogressedduringorwithin12months
ofcompletingadjuvantendocrinetherapyandwho
havenotreceivedpriorsystemictherapyforlocally
advancedormetastaticdisease.Theprimaryendpoint
wasPFSbyinvestigatorassessment. Secondary
endpointsincludedOS,investigatorassessedORR
and
Progression-free
months7.3mPFS
21.3monthmedianfollow-up
version
oninvestigatorassessment
Permanent discontinuation ratedue
toanyadversereactionswaslow
theItovebi
Mostadversereactionsweremildto
moderate(grade1-2)inthe armof
|
Themostcommon(220%)adversereactions,
includinglaboratoryabnormalities, aredecreased
neutrophils(95%),decreasedhemoglobin(88%),
increasedglucose(85%),decreasedplatelets
(84%),decreasedlymphocytes (72%),stomatitis
(51%),diarrhea(48%),decreasedcalcium(42%),
fatigue(38%),decreasedpotassium(38%),
increasedcreatinine(38%),increasedALT(34%),
nausea(28%),decreasedsodium(28%),decreased
magnesium(27%),rash(26%),decreasedalbumin
),decreasedappetite(24%),COVID-19(23%),
eadache(22%)
NationalComprehensiveCancerNetwork®
(NCCN®)testingrecommendation
NCCNGuidelines®forBreastCancer
recommendtestingforPIK3CAmutationsat
mBCdiagnosistoinformeligibilityfor
pies
makesnowarrantiesofanvkindwhatsoeverre
ent,use,or
icationorusein
comme
PleaseseethefullPrescribing Information for
additionalImportantSafetyInformation.
ImportantSafetyInformation (cont)
WarningsandPrecautions (cont)
Hyperglycemia (cont)Reduction
(95%0.32-0.59)P<0.0001
+andfulvestrant15monthsmPFS
TBased
and
mBCdiagnosistoinform
therapiesincludingthe
regimenin1LHR+/HER2inform
Seethe
Learnmoreatisib
fordetailedibility
inavoli
mE
ardingtheir
catalyticsubunitaloha; Evaluation
analysis.Presentedat:SanORR=object
PIK3CA=phosphatidylin
CriteriainSolidTum
References:5-bisohosphate
ofthe